An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy.
cancer immunotherapy
epitopes
immunogenicity
major histocompatibility complex
Journal
Antibody therapeutics
ISSN: 2516-4236
Titre abrégé: Antib Ther
Pays: United States
ID NLM: 101730822
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
26
01
2024
revised:
18
04
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Cancer immunotherapy represents a paradigm shift in oncology, offering a superior anti-tumor efficacy and the potential for durable remission. The success of personalized vaccines and cell therapies hinges on the identification of immunogenic epitopes capable of eliciting an effective immune response. Current limitations in the availability of immunogenic epitopes restrict the broader application of such therapies. A critical criterion for serving as potential cancer antigens is their ability to stably bind to the major histocompatibility complex (MHC) for presentation on the surface of tumor cells. To address this, we have developed a comprehensive database of MHC epitopes, experimentally validated for their MHC binding and cell surface presentation. Our database catalogs 451 065 MHC peptide epitopes, each with experimental evidence for MHC binding, along with detailed information on human leukocyte antigen allele specificity, source peptides, and references to original studies. We also provide the grand average of hydropathy scores and predicted immunogenicity for the epitopes. The database (MHCepitopes) has been made available on the web and can be accessed at https://github.com/jcm1201/MHCepitopes.git. By consolidating empirical data from various sources coupled with calculated immunogenicity and hydropathy values, our database offers a robust resource for selecting actionable tumor antigens and advancing the design of antigen-specific cancer immunotherapies. It streamlines the process of identifying promising immunotherapeutic targets, potentially expediting the development of effective antigen-based cancer immunotherapies.
Identifiants
pubmed: 38933532
doi: 10.1093/abt/tbae011
pii: tbae011
pmc: PMC11200702
doi:
Types de publication
Journal Article
Langues
eng
Pagination
177-186Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Antibody Therapeutics.
Déclaration de conflit d'intérêts
C.C.C. was employed by the company Biomap, Inc. The remaining authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.